Brief: PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab

PhaseBio Pharmaceuticals

15/11/2021 16:34

Nov 15 (Reuters) - PhaseBio Pharmaceuticals Inc  PHAS.O :
    * PHASEBIO ANNOUNCES INTERIM RESULTS FROM PIVOTAL REVERSE-IT
PHASE
3 TRIAL OF BENTRACIMAB FOR THE REVERSAL OF ANTIPLATELET EFFECTS
OF TICAGRELOR IN PATIENTS REQUIRING URGENT SURGERY OR
EXPERIENCING UNCONTROLLED MAJOR OR LIFE-THREATENING BLEEDING
    * PHASEBIO PHARMACEUTICALS INC - CO-PRIMARY ENDPOINT OF
CLINICAL
HEMOSTASIS ACHIEVED IN GREATER THAN 90% OF PATIENTS
    * PHASEBIO PHARMACEUTICALS INC - BENTRACIMAB APPEARED WELL
TOLERATED WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS
    * PHASEBIO PHARMACEUTICALS - PHASE 3 TRIAL OF BENTRACIMAB
ACHIEVED
PRIMARY REVERSAL ENDPOINT

Source text for Eikon:  ID:nBw6yvNmLa 
Further company coverage:  PHAS.O 

 ((Reuters.Briefs@thomsonreuters.com;))